Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study

Li Zhang,1 Shanshan Wang,2 Yuyin Zhu,1 Tianchi Yang3 1Second Department of Pulmonary Medicine, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 2Department of Psychology, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 3Department of Tuberc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang L, Wang S, Zhu Y, Yang T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Vitamin D Major depressive disorders Depression Tuberculosis Mycobacterium tuberculosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8b835397d0684cfc9f6a7bec39c6709a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b835397d0684cfc9f6a7bec39c6709a
record_format	dspace
spelling	oai:doaj.org-article:8b835397d0684cfc9f6a7bec39c6709a2021-12-02T08:22:56ZVitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study1178-2021https://doaj.org/article/8b835397d0684cfc9f6a7bec39c6709a2018-11-01T00:00:00Zhttps://www.dovepress.com/vitamin-d3-as-adjunctive-therapy-in-the-treatment-of-depression-in-tub-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Li Zhang,1 Shanshan Wang,2 Yuyin Zhu,1 Tianchi Yang3 1Second Department of Pulmonary Medicine, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 2Department of Psychology, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 3Department of Tuberculosis Control, Ningbo Municipal Center for Disease Control & Prevention, Ningbo, Zhejiang, People’s Republic of China Objective: We aimed to evaluate whether high-dose cholecalciferol has beneficial effects on depression in pulmonary tuberculosis (PTB) patients. Methods: This pilot, randomized, and double-blind trial enrolled 123 recurrent PTB patients (aged ≥18 years) meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria of major depressive disorder from four hospitals in Southeast China. Patients were randomly assigned to 8-week oral treatment with 100,000 IU/week cholecalciferol (Vit D group) or a matching placebo (control group). The primary outcome was treatment response, defined as a 50% reduction in symptoms and change in scores of the Chinese version of Beck Depression Inventory (BDI) from baseline to 8 weeks. Relative risks of depression were estimated using multivariable logistic regression. Results: Finally, 120 patients were enrolled, including 56 test patients and 64 controls. After 8 weeks, the treatment response or BDI scores did not differ significantly between groups. Multivariate logistic regression showed that BDI scores were not significantly improved in the Vit D group after adjustment for age, time to first negative smear, or 25-hydroxyvitamin D level. Conclusion: The use of high-dose Vit D3 supplementation may not be warranted for reducing depressive symptoms in the PTB population. Nevertheless, this finding should be validated by further large-scale studies according to different kinds of depression or Vit D receptor polymorphism genotype. Keywords: vitamin D, major depressive disorders, depression, tuberculosis, Mycobacterium tuberculosisZhang LWang SZhu YYang TDove Medical PressarticleVitamin DMajor depressive disordersDepressionTuberculosisMycobacterium tuberculosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 3103-3109 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Vitamin D Major depressive disorders Depression Tuberculosis Mycobacterium tuberculosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Vitamin D Major depressive disorders Depression Tuberculosis Mycobacterium tuberculosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhang L Wang S Zhu Y Yang T Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
description	Li Zhang,1 Shanshan Wang,2 Yuyin Zhu,1 Tianchi Yang3 1Second Department of Pulmonary Medicine, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 2Department of Psychology, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 3Department of Tuberculosis Control, Ningbo Municipal Center for Disease Control & Prevention, Ningbo, Zhejiang, People’s Republic of China Objective: We aimed to evaluate whether high-dose cholecalciferol has beneficial effects on depression in pulmonary tuberculosis (PTB) patients. Methods: This pilot, randomized, and double-blind trial enrolled 123 recurrent PTB patients (aged ≥18 years) meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria of major depressive disorder from four hospitals in Southeast China. Patients were randomly assigned to 8-week oral treatment with 100,000 IU/week cholecalciferol (Vit D group) or a matching placebo (control group). The primary outcome was treatment response, defined as a 50% reduction in symptoms and change in scores of the Chinese version of Beck Depression Inventory (BDI) from baseline to 8 weeks. Relative risks of depression were estimated using multivariable logistic regression. Results: Finally, 120 patients were enrolled, including 56 test patients and 64 controls. After 8 weeks, the treatment response or BDI scores did not differ significantly between groups. Multivariate logistic regression showed that BDI scores were not significantly improved in the Vit D group after adjustment for age, time to first negative smear, or 25-hydroxyvitamin D level. Conclusion: The use of high-dose Vit D3 supplementation may not be warranted for reducing depressive symptoms in the PTB population. Nevertheless, this finding should be validated by further large-scale studies according to different kinds of depression or Vit D receptor polymorphism genotype. Keywords: vitamin D, major depressive disorders, depression, tuberculosis, Mycobacterium tuberculosis
format	article
author	Zhang L Wang S Zhu Y Yang T
author_facet	Zhang L Wang S Zhu Y Yang T
author_sort	Zhang L
title	Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
title_short	Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
title_full	Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
title_fullStr	Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
title_full_unstemmed	Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
title_sort	vitamin d3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/8b835397d0684cfc9f6a7bec39c6709a
work_keys_str_mv	AT zhangl vitamind3asadjunctivetherapyinthetreatmentofdepressionintuberculosispatientsashorttermpilotrandomizeddoubleblindcontrolledstudy AT wangs vitamind3asadjunctivetherapyinthetreatmentofdepressionintuberculosispatientsashorttermpilotrandomizeddoubleblindcontrolledstudy AT zhuy vitamind3asadjunctivetherapyinthetreatmentofdepressionintuberculosispatientsashorttermpilotrandomizeddoubleblindcontrolledstudy AT yangt vitamind3asadjunctivetherapyinthetreatmentofdepressionintuberculosispatientsashorttermpilotrandomizeddoubleblindcontrolledstudy
_version_	1718398554784923648

Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study

Ejemplares similares